TABLE 3.
Proportion (95% CI) of Patients Receiving 8, 12, 16, and 24 Weeks of Therapy
| Duration of Therapy | SIM/SOF % (95% CI) | LDV/SOF % (95% CI) | OPrD % (95% CI) | SOF/VEL % (95% CI) | EBR/GZR % (95% CI) | GLE/PIB % (95% CI) |
|---|---|---|---|---|---|---|
| 8 weeks | ||||||
| Overall cohort | 6.0 (5.0-7.0) | 24.0 (23.4-24.6) | 5.3 (4.4-6.1) | 4.6 (3.7-5.5) | 5.5 (4.3-6.7) | 74.9 (68.8-80.9) |
| Noncirrhotic | 6.1 (4.8-7.3) | 28.7 (27.9-29.4) | 4.8 (3.9-5.7) | 4.4 (3.4-5.4) | 5.2 (3.9-6.5) | 78.1 (72.1-84.0) |
| Cirrhotic | 6.0 (4.4-7.5) | 5.7 (4.9-6.4) | 8.2 (5.4-11.1) | 5.5 (3.2-7.8) | 6.6 (3.7-9.5) | 25.0 (0.5-49.5) |
| 12 weeks | ||||||
| Overall cohort | 79.5 (77.8-81.2) | 61.4 (60.7-62.2) | 73.0 (71.3-74.8) | 90.1 (88.8-91.5) | 85.4 (83.5-87.3) | 16.1 (9.7-22.6) |
| Noncirrhotic | 81.2 (79.0-83.3) | 61.3 (60.5-62.2) | 77.2 (75.4-78.9) | 91.2 (89.8-92.6) | 86.2 (84.1-88.3) | 12.1 (6.1-18.0) |
| Cirrhotic | 77.1 (74.3-79.9) | 61.8 (60.2-63.4) | 46.8 (41.6-52.1) | 85.4 (81.8-89.0) | 82.4 (77.9-86.9) | 75.0 (45.0-100) |
| 16 weeks | ||||||
| Overall cohort | 2.8 (2.1-3.5) | 1.6 (1.4-1.8) | 1.6 (1.1-2.1) | 1.4 (0.8-1.9) | 5.5 (4.2-6.8) | 2.7 (0.0-7.9) |
| Noncirrhotic | 2.7 (1.8-3.5) | 1.4 (1.2-1.6) | 1.3 (0.9-1.8) | 1.1 (0.5-1.6) | 4.6 (3.3-6.0) | 2.9 (0.0-8.6) |
| Cirrhotic | 2.9 (1.8-4.1) | 2.4 (1.9-2.9) | 3.2 (1.3-5.0) | 2.7 (1.0-4.4) | 8.6 (5.2-12.1) | 0.0 (0-0) |
| 24 weeks | ||||||
| Overall cohort | 3.1 (2.4-3.9) | 8.8 (8.3-9.2) | 8.6 (7.5-9.7) | 0.7 (0.3-1.1) | 0.2 (0.0-0.5) | 0 |
| Noncirrhotic | 1.9 (1.1-2.6) | 4.7 (4.4-5.1) | 6.1 (5.1-7.1) | 0.2 (0.0-0.4) | 0.1 (0.0-0.4) | 0 |
| Cirrhotic | 5.0 (3.5-6.6) | 24.4 (22.9-25.8) | 24.3 (19.7-28.9) | 2.9 (0.9-4.9) | 0.5 (0.0-1.4) | 0 |
CI = confidence interval; EBR/GZR = elbasvir/grazoprevir; GLE/PIB = glecaprevir/pibrentasvir; LDV/SOF = ledipasvir/sofosbuvir; OPrD = ombitasvir/paritaprevir/ritonavir + dasabuvir; SIM/SOF = simeprevir/sofosbuvir; SOF/VEL = sofosbuvir/velpatasvir.